Compare ArcelorMittal SA (MT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Zoetis Inc — how do they compare? ArcelorMittal SA trades at $64.22 (market cap $45.70B), while Zoetis Inc trades at $74.58 (market cap $30.20B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and Zoetis Inc for 70 Days on average.
| MT | ZTS | |
|---|---|---|
Market Cap | $45.70B | $30.20B |
Volume | 1,964,621 | 6,175,327 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $147.53 |
52-Week Low | $36.91 | $69.09 |
Typical Hold Time | 36 Days | 70 Days |
Enterprise Value | $55.27B | $37.76B |
Dividend Yield | 0.98% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $64.18, up 2.98% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains solid fundamentals with a P/E of 25.76 and P/S of 0.75, though recent Q2 2026 earnings missed expectations. Revenue has declined from $79.8B in 2022 to $61.4B in 2025, while net income improved to $3.2B. Recent news highlights operational challenges in Ukraine with a $1B impairment charge, but strategic partnerships and European demand improvements provide offsetting positives.
The outlook remains cautiously optimistic with analyst consensus price target of $74.33 representing 16% upside potential. Key opportunities include expanding steel capacity and regionalization benefits, while risks involve ongoing Ukraine operations disruption, China demand weakness, and elevated capital expenditures. Institutional sentiment leans bullish with 52% buy ratings, though technical resistance near $62-63 may limit near-term gains.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
